Study of ALKS 2680 for narcolepsy type 2
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study tests an investigational drug called ALKS 2680 for people with narcolepsy type 2, a condition that causes excessive daytime sleepiness without sudden muscle weakness. The goal is to see if the drug is safe and helps reduce daytime sleepiness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with narcolepsy type 2, based on a sleep study and daytime nap test.
- You do not have another sleep disorder (like sleep apnea) that could affect your sleep-wake cycle.
- You are generally healthy, without other serious medical conditions that could interfere with the study.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
- You are not currently in another clinical trial and have not been in one in the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people with narcolepsy or idiopathic hypersomnia who have already taken part in an earlier ALKS 2680 study. It aims to see how well the medication works and how safe it is when taken for a longer time.
This study tests a new medicine called TAK-360 for people with narcolepsy type 2 (narcolepsy without cataplexy). It aims to see if the drug safely reduces daytime sleepiness.
This trial tests an experimental drug called ORX750 for people with narcolepsy or idiopathic hypersomnia. You would need to stop your current sleepiness medicines to see if ORX750 helps reduce daytime sleepiness.
This study tests whether a new medication called cleminorexton helps people with narcolepsy (a condition causing severe daytime sleepiness) sleep better and feel more alert. You would take this medication instead of your current narcolepsy drugs for several months to see if it works.
This is a follow-up study for people who already completed a TAK-360 trial for narcolepsy (a sleep disorder causing sudden sleep attacks) or idiopathic hypersomnia (excessive daytime sleepiness). Researchers want to see if continuing TAK-360 remains safe and effective for you.
This study looks at people with narcolepsy type 1 or type 2 in Spain to learn more about these conditions. If you or your child has a confirmed diagnosis, you may be able to take part.
Hear when a new Narcolepsy Type 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.